Cargando…

A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex

Serosurveillance and seroprevalence studies are an essential tool to monitor vaccine-preventable diseases. We have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), fil...

Descripción completa

Detalles Bibliográficos
Autores principales: Caboré, Raissa Nadège, Piérard, Denis, Huygen, Kris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931633/
https://www.ncbi.nlm.nih.gov/pubmed/27171114
http://dx.doi.org/10.3390/vaccines4020016
_version_ 1782440934123765760
author Caboré, Raissa Nadège
Piérard, Denis
Huygen, Kris
author_facet Caboré, Raissa Nadège
Piérard, Denis
Huygen, Kris
author_sort Caboré, Raissa Nadège
collection PubMed
description Serosurveillance and seroprevalence studies are an essential tool to monitor vaccine-preventable diseases. We have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn). The in-house pentaplex MIA showed a good correlation with commercial ELISAs with correlation coefficients between 0.89 for PT and 0.98 for TT. Intra- and inter-assay variability was <10%. A total of 670 anonymized serum samples collected in 2012 in Belgian adults (ages 20–29.9 years) were analyzed. Geometric mean concentrations (GMC) were 0.2 (0.13–0.29) IU/mL for DT, 0.63 (0.45–0.82) IU/mL for TT, 3.9 (2.6–5.8) IU/mL for PT, 16.3 (11.7–22.7) IU/mL for FHA and 15.4 (10.1–23.6) IU/mL for Prn. Antibody concentrations were below the protective level of 0.1 IU/mL in 26.4% of the sera for DT and in 8.6% of the sera for TT. Anti-PT IgG concentrations indicative of recent pertussis infection (>125 IU/mL) were detected in 1.2% of the subjects. High anti-PT antibodies were not correlated with high antibodies against any of the four other vaccine antigens. This pentaplex MIA will be used for a new large-scale Belgian serosurveillance/seroprevalence study of diphtheria, tetanus and pertussis.
format Online
Article
Text
id pubmed-4931633
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-49316332016-07-08 A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex Caboré, Raissa Nadège Piérard, Denis Huygen, Kris Vaccines (Basel) Article Serosurveillance and seroprevalence studies are an essential tool to monitor vaccine-preventable diseases. We have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn). The in-house pentaplex MIA showed a good correlation with commercial ELISAs with correlation coefficients between 0.89 for PT and 0.98 for TT. Intra- and inter-assay variability was <10%. A total of 670 anonymized serum samples collected in 2012 in Belgian adults (ages 20–29.9 years) were analyzed. Geometric mean concentrations (GMC) were 0.2 (0.13–0.29) IU/mL for DT, 0.63 (0.45–0.82) IU/mL for TT, 3.9 (2.6–5.8) IU/mL for PT, 16.3 (11.7–22.7) IU/mL for FHA and 15.4 (10.1–23.6) IU/mL for Prn. Antibody concentrations were below the protective level of 0.1 IU/mL in 26.4% of the sera for DT and in 8.6% of the sera for TT. Anti-PT IgG concentrations indicative of recent pertussis infection (>125 IU/mL) were detected in 1.2% of the subjects. High anti-PT antibodies were not correlated with high antibodies against any of the four other vaccine antigens. This pentaplex MIA will be used for a new large-scale Belgian serosurveillance/seroprevalence study of diphtheria, tetanus and pertussis. MDPI 2016-05-10 /pmc/articles/PMC4931633/ /pubmed/27171114 http://dx.doi.org/10.3390/vaccines4020016 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Caboré, Raissa Nadège
Piérard, Denis
Huygen, Kris
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
title A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
title_full A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
title_fullStr A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
title_full_unstemmed A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
title_short A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex
title_sort belgian serosurveillance/seroprevalence study of diphtheria, tetanus and pertussis using a luminex xmap technology-based pentaplex
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4931633/
https://www.ncbi.nlm.nih.gov/pubmed/27171114
http://dx.doi.org/10.3390/vaccines4020016
work_keys_str_mv AT caboreraissanadege abelgianserosurveillanceseroprevalencestudyofdiphtheriatetanusandpertussisusingaluminexxmaptechnologybasedpentaplex
AT pierarddenis abelgianserosurveillanceseroprevalencestudyofdiphtheriatetanusandpertussisusingaluminexxmaptechnologybasedpentaplex
AT huygenkris abelgianserosurveillanceseroprevalencestudyofdiphtheriatetanusandpertussisusingaluminexxmaptechnologybasedpentaplex
AT caboreraissanadege belgianserosurveillanceseroprevalencestudyofdiphtheriatetanusandpertussisusingaluminexxmaptechnologybasedpentaplex
AT pierarddenis belgianserosurveillanceseroprevalencestudyofdiphtheriatetanusandpertussisusingaluminexxmaptechnologybasedpentaplex
AT huygenkris belgianserosurveillanceseroprevalencestudyofdiphtheriatetanusandpertussisusingaluminexxmaptechnologybasedpentaplex